Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Declines By 55.5%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 33,109 shares, a decrease of 55.5% from the December 15th total of 74,418 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 265,842 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 265,842 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Xtant Medical Price Performance

Shares of XTNT stock traded up $0.01 during trading hours on Friday, hitting $0.67. The stock had a trading volume of 124,205 shares, compared to its average volume of 172,353. Xtant Medical has a one year low of $0.34 and a one year high of $0.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. The stock’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.68. The stock has a market capitalization of $93.10 million, a price-to-earnings ratio of 66.57 and a beta of -0.08.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Monday, November 10th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. bought a new stake in Xtant Medical during the 2nd quarter valued at about $4,875,000. Vanguard Group Inc. grew its stake in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares in the last quarter. Crescent Grove Advisors LLC increased its position in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after acquiring an additional 200,000 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after acquiring an additional 57,000,000 shares in the last quarter. Finally, Mink Brook Asset Management LLC raised its stake in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after acquiring an additional 60,997 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, BTIG Research reduced their target price on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Xtant Medical presently has an average rating of “Buy” and a consensus target price of $1.50.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.